Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
4.890
+0.050 (1.03%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Lexeo Therapeutics Employees
Lexeo Therapeutics had 63 employees as of June 30, 2026. The number of employees increased by 2 or 3.28% compared to the same quarter last year.
Employees
63
Change
2
Growth
3.28%
Revenue / Employee
n/a
Profits / Employee
-$1,385,159
Market Cap
401.19M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 63 | 2 | 3.28% |
| Mar 31, 2026 | 59 | -16 | -21.33% |
| Dec 31, 2025 | 59 | -13 | -18.06% |
| Sep 30, 2025 | 61 | -11 | -15.28% |
| Jun 30, 2025 | 61 | -8 | -11.59% |
| Mar 31, 2025 | 75 | 17 | 29.31% |
| Dec 31, 2024 | 72 | 14 | 24.14% |
| Sep 30, 2024 | 72 | 14 | 24.14% |
| Jun 30, 2024 | 69 | - | - |
| Dec 31, 2023 | 58 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| EyePoint | 214 |
| Rocket Pharmaceuticals | 202 |
| Enanta Pharmaceuticals | 120 |
| Zentalis Pharmaceuticals | 106 |
| Agenus | 81 |
| Century Therapeutics | 78 |
| Larimar Therapeutics | 71 |
| X4 Pharmaceuticals | 45 |
LXEO News
- 5 days ago - Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September - GlobeNewsWire
- 21 days ago - Lexeo Therapeutics reports Q2 EPS (30c), consensus (28c) - TheFly
- 26 days ago - Lexeo Therapeutics Slides: Corporate presentation - Filings
- 26 days ago - Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights - GlobeNewsWire
- 26 days ago - Lexeo Therapeutics Earnings release: Q2 2026 - Filings
- 26 days ago - Lexeo Therapeutics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Lexeo Therapeutics management to meet with Cantor - TheFly
- 4 weeks ago - Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy - GlobeNewsWire